2Vakil N,van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence - based consensus [ J ]. Am J Gastroenterol,2006,101 (8):1900-1920.
5Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 2003, 98 (3Suppl): 2-7.
6Graham DY. The changing epidemiology of GERD: geography and helicobacter pylori. Am J Gastroenterol, 2003, 98: 1462-1470.
7Ofman JJ. The economic and quality of life impact of symptom atic gastroesophageal reflux disease. Am J Gastroenterol,2003, 98 suppl. 8-14.
8Bardhan KD. Intermittent and on- demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol, 2003, 98 suppl. 40-48.
9Cremonini F, Di Caro S, Delgado - Aros S, et al. Meta - analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther,2003, 18: 279-289.
10Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobater pylori eradication on heartburn in patients with gastric or duode nal ulcer disease: results from a randomized trial program. Ali ment Pharmacol Ther, 2002, 16: 1431～1442.
